Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson
Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy
Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…Case study: Real-time MRI articulatory comparison of a congenital aglossic and normal speaker
Objective: Congenital aglossia is a rare syndrome of born without a tongue. This paper examines articulatory movements of a congenital aglossic speaker to understand physiology by…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Treatable Rare Movement Disorders
Objective: To classify therapies of RMD into enzyme replacement therapy, specific dietary changes, avoidance or management of certain triggers, and others Background: Rare diseases (RD)…Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression
Objective: To evaluate to predictors of the disease-modifying effect of drugs on Parkinson’s disease (DM-PD) according to long-term therapeutic investigation, especially regarding the non-dopaminergic agent…Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy
Objective: Test the hypothesis that combining humoral and immunosuppressive cellular asyn immunization will enhance asyn clearance, and reduce inflammation and neuropathological symptoms in a human…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease
Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »